Business Daily Media

Men's Weekly

.

Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations

  • Brings over 20 years of clinical experience, including management of Phase 1-2 clinical trials in a variety of indications such as ophthalmology
  • Will oversee all R&D operations with focus on clinical development and operations

Kensington, MD, USA - EQS Newswire - 25 October 2023 - Galimedix Therapeutics, Inc.

("Galimedix"), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, today announced the appointment of Luciana Summo, PhD, as Vice President, R&D Operations. In this newly created position, she will oversee all activities related to R&D operations, with an emphasis on clinical development and operations. This includes spearheading the design, planning, and execution of clinical trials. Dr. Summo reports to Hermann Russ, MD, PhD, Co-founder and Chief Scientific Officer.

"We are delighted to welcome Luciana to Galimedix," said Alexander Gebauer, MD, PhD, Co-founder and Executive Chairman. "She brings strong experience setting up and running clinical trials and ensuring that all of the proper support structures are put in place. As we move our lead product candidate, GAL-101, into Phase 2 testing for the treatment of dry age-related macular degeneration, her skill set is the perfect fit for this next stage in our development. Luciana will play a pivotal role in defining Galimedix's overall R&D strategy and driving our R&D initiatives forward. All of us very much look forward to working with her as we contribute to advancing innovative healthcare solutions that have the potential to improve the lives of patients."

Dr. Summo has over 20 years of experience in clinical development and operations, including the management of Phase 1-2 clinical trials in several indications such as ophthalmology, cardiology, and oncology. Prior to joining Galimedix, she worked in positions of increasing responsibility in the clinical departments at OMEICOS Therapeutics GmbH, NOXXON Pharma AG, and Berlin-Chemie AG/ Menarini Group. She is well versed in setting up and overseeing clinical trials on a global scale and has played a key role in transitioning programs from pre-clinical to clinical stage. She has experience with the entire spectrum of activities related to R&D operations, with a special emphasis on clinical development and clinical operations, including also quality management and CMC. She works closely with cross-functional teams, including CROs, scientists, clinicians, regulatory affairs specialists, and different stakeholders, to ensure that trials are conducted in accordance with rigorous scientific standards and regulatory guidelines. Dr. Summo has experience in submitting Clinical Trial Applications (CTAs) in Europe and Investigational New Drug (IND) applications in the US and prepared for and participated in pre-IND meetings with the US Food and Drug Administration (FDA), as well as regulatory agency meetings in Europe. She also has set up from scratch and run a clinical operations department.

Luciana Summo, PhD, Vice President, R&D Operations, added: "I am truly excited to be joining Galimedix at this important point in the Company's growth. The programs in ophthalmology and Alzheimer's disease have the potential to change the treatment paradigm, and I look forward to working with the rest of the team to bring them forward in the clinic."
Hashtag: #Galimedix

The issuer is solely responsible for the content of this announcement.

About Galimedix Therapeutics, Inc.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix's groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry age-related macular degeneration (AMD), glaucoma and Alzheimer's disease - Galimedix's initial areas of focus. The Company's approach targets toxic Aβ oligomers and protofibrils. Many studies have indicated that these oligomers and protofibrils are an underlying cause of neurodegenerative diseases of the eye. And, recent approvals and promising Phase 3 results of anti-Aβ drugs also have validated them as a key target in Alzheimer's disease. Compelling pre-clinical data support the potential of Galimedix's product candidates to slow or stop neurodegeneration and also restore lost neuronal function. A Phase 2 proof-of-concept study in dry AMD with lead program, topical GAL-101, is in preparation with strong support from partner, Théa Open Innovation (TOI). Clinical studies in other indications are planned.

News from Asia

ANDPAD Launches Vietnamese Language Support for its Cloud-Based Construction Project Management Service

Expanding Multilingual Support for Global Users TOKYO, JAPAN - Media OutReach Newswire - 26 June 2025 - ANDPAD Inc. (Head Office: Chiyoda-ku, Tokyo; CEO: Takeo Inada; hereinafter ANDPAD), which op...

Changhong Unveils Smart Living Innovations at 2025 Jakarta Expo, Bringing AI-Driven Appliances to Indonesian Homes

Exclusive Shopee partnership brings cutting-edge smart living technology to Indonesian consumers JAKARTA, INDONESIA - Media OutReach Newswire - 24 June 2025 - Changhong, a global leader in smart ...

Malaysia Launches Full-Scale Startup ASEAN Platform To Drive Regional Growth

PUTRAJAYA, MALAYSIA - Media OutReach Newswire - 26 June 2025 - Malaysia today launched the Startup ASEAN platform, marking the full-scale rollout of a bold, unified digital gateway to connect and e...

Hong Kong Civil Claim Centre Launches Free Work Injury Compensation Calculator

HONG KONG SAR - Media OutReach Newswire - 26 June 2025 - The Hong Kong Civil Claim Centre (hkcivilclaim.com) has officially launched a brand-new online feature: the Work Injury Compensation Calcu...

Deleted

This Press release has been killed

SiegFund Transforms into SiegPath: A Strategic Rebrand Paving the Way for the Future of Professional Trading

HONG KONG SAR - Media OutReach Newswire - 24 June 2025 - SiegFund, a fintech–driven proprietary trading platform, has officially completed its brand upgrade and will now operate as SiegPath, serv...

Plaza 66’s Pavilion Extension Tops Out, Opening in Second Half of 2026

Expanding Retail Space by 13% to Boost the New Consumption Economy in Shanghai HONG KONG SAR & SHANGHAI, CHINA - Media OutReach Newswire - 26 June 2025 - Hang Lung Properties Limited (SEHK sto...

New EcoFood@Mandai Development Offers Tailored Food Factory Spaces in the North

SINGAPORE - Media OutReach Newswire - 26 June 2025 - A new food factory hub, EcoFood@Mandai, has officially launched in Singapore’s northern region, bringing purpose-built factory units to a wide ...

GREE Opens Singapore Office to Drive Asia-Pacific Expansion with World-Class Air Conditioning Technologies

SINGAPORE - Media OutReach Newswire - 26 June 2025 - Global electronics manufacturer GREE has officially launched its Singapore branch, marking a key milestone in its expansion in Southeast Asia. ...

HONMA Golf Announces Annual Results for FY2024/25

Continued Gross Profit Margin and Net Operating Cash Flow improvements albeit difficult market conditions HONG KONG SAR - Media OutReach Newswire - 26 June 2025 - HONMA Golf Limited ("HONMA"; tog...

Demand for Home Batteries surges as Federal Rebate Kicks In

A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...

Why Sport Remains the Safest Bet in an Uncertain World

When Rome was in crisis, its leaders did not retreat to the Senate. They went to the circus. To the chariot races. To the gladiators. Sport was no...

THE FINE LINE WITHIN HILARIOUS SIGNAGE DESIGN FAILS

It seems like design failures still occur in today’s modern branding era, despite rigorous rounds of approvals behind the scenes. One signage show...

Deputy Announces Exclusive Global Partnership with Predelo to Bring AI to Shift-Based Businesses

Deputy, the global people platform for shift-based businesses, has announced an exclusive partnership with Predelo, an AI Decision Agent-as-a-Serv...

Leftover Budget? The Last-Minute EOFY Tip to Drive Business Success in FY25/26

The countdown is on. With just days left until EOFY, now’s the time to make your remaining 2024–2025 budget work harder and smarter. After workin...

pay.com.au appoints new CEO and Managing Director

The former COO will lead the company’s next growth phase, with ex-CEO Edward Alder transitioning into the role of Managing Director AUSTRALIA, 25...

Sell by LayBy